Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Visible Lesions in Barrett’s Esophagus During EET

J Clin Gastroenterol; ePub 2019 Jan 4; Thota, et al

In a single center study of patients referred for endoscopic eradication therapy (EET) of Barrett’s esophagus (BE), approximately 19% of BE patients developed visible lesions (VL) during EET. Demographic data, endoscopic findings, histologic findings, and response to EET were analyzed. Researchers assessed outcomes of EET in BE patients with VL and BE patients with flat dysplasia. They found:

  • 264 patients were included in the analysis; 34 had flat dysplasia, 180 had VL before initiating EET (prevalent lesions), and 50 developed VL during EET (incident lesions).
  • There was a higher prevalence of high-grade dysplasia (HGD)/esophageal adenocarcinoma (EAC) in prevalent VL compared with incident VL.
  • There were no significant differences in eradication of metaplasia/dysplasia between the groups.

Citation:

Thota PN, Benjamin T, Sanaka MR, et al. Clinical outcomes based on the timing of appearance of visible lesions in Barrett’s esophagus during endoscopic eradication therapy. [Published online ahead of print January 4, 2019]. J Clin Gastroenterol. doi:10.1097/MCG.0000000000001165.

Must Reads in Endoscopy, Pancreas, & Biliary Tract

Gender Differences in Patients Hospitalized with Cirrhosis, J Clin Gastroenterol; ePub 2019 Feb 22; Rubin, et al

POC Test for Identifying Viraemic HCV Infection, J Hepatol; ePub 2019 Feb 21; Freiman, et al

Frailty in Patients with Ascites & Hepatic Encephalopathy, Gastroenterology; ePub 2019 Jan 19; Lai, et al

Hypercholesterolemia & Statin Exposure in Cirrhosis, Gastroenterology; ePub 2019 Jan 18; Kaplan, et al

Response to UDCA Treatment in PBC Patients, Clin Gastroenterol Hepatol; ePub 2019 Jan 4; Cheung, et al